WO2005114207A3 - Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep) - Google Patents
Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep) Download PDFInfo
- Publication number
- WO2005114207A3 WO2005114207A3 PCT/EP2005/004727 EP2005004727W WO2005114207A3 WO 2005114207 A3 WO2005114207 A3 WO 2005114207A3 EP 2005004727 W EP2005004727 W EP 2005004727W WO 2005114207 A3 WO2005114207 A3 WO 2005114207A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- anpep
- aminopeptidase
- therapeutics
- diagnostics
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 102100022749 Aminopeptidase N Human genes 0.000 title abstract 2
- 108010049990 CD13 Antigens Proteins 0.000 title abstract 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 title 1
- 101150058497 ANPEP gene Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 101100216012 Homo sapiens ANPEP gene Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne une ANPEP humaine qui est associée aux maladies cardiovasculaires, au cancer, aux maladies dermatologiques, aux maladies endocrines, aux maladies métaboliques, à l'inflammation, aux maladies gastro-entérologiques, aux maladies hématologiques et aux maladies urologiques. L'invention concerne également des analyses permettant d'identifier des composés utiles dans le traitement ou la prévention des maladies cardiovasculaires, du cancer, des maladies dermatologiques, des maladies endocrines, des maladies métaboliques, de l'inflammation, des maladies gastro-entérologiques, des maladies hématologiques et des maladies urologiques. L'invention concerne enfin des composés qui se lient à une ANPEP et/ou activent ou inhibent l'activité d'une ANPEP ainsi que les compositions pharmaceutiques comprenant ces composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04011364 | 2004-05-13 | ||
| EP04011364.9 | 2004-05-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005114207A2 WO2005114207A2 (fr) | 2005-12-01 |
| WO2005114207A3 true WO2005114207A3 (fr) | 2006-04-27 |
Family
ID=35414806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/004727 WO2005114207A2 (fr) | 2004-05-13 | 2005-04-30 | Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005114207A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007087370A2 (fr) * | 2006-01-25 | 2007-08-02 | Caprion Pharmaceuticals, Inc. | Tat-038 et méthodes d'évaluation et de traitement du cancer |
| GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
| US11244760B2 (en) | 2015-06-25 | 2022-02-08 | Karydo Therapeutix, Inc. | Prediction device based on inter-organ cross talk system |
| JP6432962B2 (ja) | 2016-03-29 | 2018-12-05 | 株式会社国際電気通信基礎技術研究所 | 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法 |
| EP3466446B1 (fr) | 2016-03-29 | 2023-12-27 | Karydo Therapeutix, Inc. | Composition pharmaceutique ou composition alimentaire et procédé d'évaluation de l'effet d'un principe actif in vivo |
| CN110438207B (zh) * | 2019-09-04 | 2023-03-28 | 康妍葆(北京)干细胞科技有限公司 | 一种鉴定牙囊干细胞的引物、试剂、试剂盒、鉴定方法及应用 |
| AU2021283390A1 (en) | 2020-06-03 | 2023-01-19 | Esn Cleer | Biomarker identification for imminent and/or impending heart failure |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180084B1 (en) * | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
-
2005
- 2005-04-30 WO PCT/EP2005/004727 patent/WO2005114207A2/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180084B1 (en) * | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
Non-Patent Citations (2)
| Title |
|---|
| IKEDA NAOYA ET AL: "Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. APR 2003, vol. 9, no. 4, April 2003 (2003-04-01), pages 1503 - 1508, XP009058193, ISSN: 1078-0432 * |
| RÖCKEN C ET AL: "Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.", JOURNAL OF CLINICAL PATHOLOGY. OCT 2005, vol. 58, no. 10, October 2005 (2005-10-01), pages 1069 - 1075, XP009058183, ISSN: 0021-9746 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005114207A2 (fr) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004104216A3 (fr) | Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) | |
| WO2006027147A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr) | |
| WO2005106012A3 (fr) | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1) | |
| WO2005114207A3 (fr) | Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep) | |
| WO2006010517A3 (fr) | Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap) | |
| WO2005103684A3 (fr) | Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c | |
| WO2005075675A3 (fr) | Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1) | |
| WO2006021343A3 (fr) | Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a) | |
| WO2005076007A3 (fr) | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) | |
| WO2005031358A3 (fr) | Agents diagnostiques et therapeutiques pour des maladies associees a une exopeptidase de type rnpep a base d'aminopeptidase d'arginyle | |
| WO2005085466A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 2 associee a rho (rock2) | |
| WO2005090994A3 (fr) | Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1) | |
| WO2005113786A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) | |
| WO2005073729A3 (fr) | Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11) | |
| WO2005026719A3 (fr) | Diagnostic et traitement de maladies associees au transporteur de cations organiques slc22a3 (slc22a3) | |
| WO2006013013A3 (fr) | Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb) | |
| WO2005054867A3 (fr) | Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5) | |
| WO2006013014A3 (fr) | Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal) | |
| WO2004104595A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd) | |
| WO2005085469A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 1 associee a rho (rock1) | |
| WO2005095953A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6) | |
| WO2005075983A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3) | |
| WO2005075666A3 (fr) | Outils de diagnostic et de traitement de maladies associees a l'aminopeptidase sensible a la puromycine npepps (npepps) | |
| WO2005040791A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) | |
| WO2005093426A3 (fr) | Diagnostics et therapeutiques pour des maladies associees au recepteur d'acide retinoique alpha (rara) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |